Stoke Therapeutics (STOK)
(Real Time Quote from BATS)
$11.31 USD
-0.35 (-3.00%)
Updated Apr 25, 2024 12:13 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Stoke Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 12 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 9 | 12 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 124 | 117 | 86 | 53 | 36 |
Income After Depreciation & Amortization | -115 | -104 | -86 | -53 | -36 |
Non-Operating Income | 10 | 3 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -105 | -101 | -86 | -52 | -32 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -105 | -101 | -86 | -52 | -32 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -105 | -101 | -86 | -52 | -32 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -113 | -103 | -85 | -52 | -35 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -115 | -104 | -86 | -53 | -36 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.00 | 38.90 | 36.74 | 33.49 | 17.97 |
Diluted EPS Before Non-Recurring Items | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 |
Diluted Net EPS (GAAP) | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 |
Fiscal Year end for Stoke Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 2.80 | 3.31 | -2.48 | 5.15 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 2.80 | 3.31 | -2.48 | 5.15 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 32.39 | 30.54 | 30.78 | 29.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -29.59 | -27.23 | -33.26 | -24.69 |
Non-Operating Income | NA | 2.63 | 2.69 | 2.61 | 2.15 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -26.96 | -24.54 | -30.65 | -22.55 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -26.96 | -24.54 | -30.65 | -22.55 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -26.96 | -24.54 | -30.65 | -22.55 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 44.96 | 44.27 | 44.19 | 42.54 |
Diluted EPS Before Non-Recurring Items | NA | -0.60 | -0.55 | -0.69 | -0.53 |
Diluted Net EPS (GAAP) | NA | -0.61 | -0.55 | -0.69 | -0.53 |